CYCC insider transaction filings
Cyclacel Pharmaceuticals, Inc. — 13 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-09-10. Screen CYCC transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CYCC between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Cyclacel Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-09-10 | 4 | Kua Khai Loon — 10% owner | Sale (S): 19,054 @ $7.01 | EDGAR |
| 2025-09-04 | 4 | Kua Khai Loon — 10% owner | Other (J): 186,465 · Other (J): 186,465 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Yap Kim Choy — 10% owner | Other (J): 186,465 · Other (J): 186,465 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Ong Yee Lung — 10% owner | Other (J): 186,465 · Other (J): 186,465 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | Lazar David E. — 10% owner | Sale (S): 6,750 @ $12.36 | EDGAR |
| 2025-02-28 | 4 | NATAN DAVID — Director | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Lazar David E. — Interim CEO, 10% owner | Option exercise (M): 2,650,000 · Option exercise (M): 191,978,820 · Sale (S): 194,628,820 @ $0.03 · Option exercise (M): 1,000,000 (derivative) · Option exercise (M): 1,745,262 (derivative) | EDGAR |
| 2025-02-28 | 4 | Ben-Tzvi Avraham — Director | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Lazar David E. — Interim CEO, 10% owner | Grant/award (A): 2,100,000 (derivative) | EDGAR |
| 2025-01-07 | 4 | NATAN DAVID — Director | Grant/award (A): 100,000 | EDGAR |
| 2024-01-31 | 4 | SCHWARTZ BRIAN — Interim Chief Medical Officer, Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | McBarron Paul — See Remarks, Director | Purchase (P): 1,886 @ $3.31 · Purchase (P): 1,886 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Rombotis Spiro George — President and CEO, Director | Purchase (P): 6,070 @ $3.31 · Purchase (P): 6,070 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cyclacel Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-12 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CYCC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →